{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:12:14Z","timestamp":1791994334876,"version":"4.4.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ekir.2023.01.041","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T06:40:25Z","timestamp":1675924825000},"page":"968-979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":67,"title":["Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study"],"prefix":"10.1016","volume":"8","author":[{"given":"Dana V.","family":"Rizk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5639-0210","authenticated-orcid":false,"given":"Brad H.","family":"Rovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Maes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-4811","authenticated-orcid":false,"given":"Hern\u00e1n","family":"Trimarchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitrij","family":"Kollins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olympia","family":"Papachristofi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Charney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2023.01.041_bib1","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1056\/NEJMra1206793","article-title":"IgA nephropathy","volume":"368","author":"Wyatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2023.01.041_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.1","article-title":"IgA nephropathy","volume":"2","author":"Lai","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ekir.2023.01.041_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.semnephrol.2007.10.001","article-title":"Natural history of primary IgA nephropathy","volume":"28","author":"Berthoux","year":"2008","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.ekir.2023.01.041_bib4","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","article-title":"Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population","volume":"27","author":"Le","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.01.041_bib5","doi-asserted-by":"crossref","first-page":"677","DOI":"10.2215\/CJN.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.01.041_bib6","article-title":"Predicting progression of IgA nephropathy: new clinical progression risk score","volume":"7","author":"Xie","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2023.01.041_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.3389\/fimmu.2019.00504","article-title":"The emerging role of complement proteins as a target for therapy of IgA nephropathy","volume":"10","author":"Rizk","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.01.041_bib8","first-page":"2493","article-title":"An update on the current state of management and clinical trials for IgA nephropathy","volume":"10","author":"Cheung","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ekir.2023.01.041_bib9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.01.041_bib10","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ekir.2023.01.041_bib13","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.01.041_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","article-title":"IgA nephropathy: core curriculum 2021","volume":"78","author":"Pattrapornpisut","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.01.041_bib15","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement activation in IgA nephropathy","volume":"43","author":"Medjeral-Thomas","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ekir.2023.01.041_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.ackd.2019.12.004","article-title":"Complement in IgA nephropathy: the role of complement in the pathogenesis, diagnosis, and future management of IgA nephropathy","volume":"27","author":"Medjeral-Thomas","year":"2020","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.ekir.2023.01.041_bib17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/ng.787","article-title":"Genome-wide association study identifies susceptibility loci for IgA nephropathy","volume":"43","author":"Gharavi","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ekir.2023.01.041_bib18","doi-asserted-by":"crossref","first-page":"7926","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ekir.2023.01.041_bib19","unstructured":"Barratt J. Final 12-week endpoint analyses of a phase 2 dose-ranging study to investigate the efficacy and safety of iptacopan in primary IgA nephropathy. Late Breaking Clinical Trial Presentation at 58th ERA-EDTA Congress, Fully Virtual, June 5\u20138, 2021."},{"key":"10.1016\/j.ekir.2023.01.041_bib20","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/j.ekir.2022.01.577","article-title":"POS-546 efficacy and safety of iptacopan in IgA nephropathy: results of a randomized double-blind placebo-controlled phase 2 study at 6 months","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.01.041_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.20203110S155c","article-title":"LNP023: a novel oral complement alternative pathway factor B inhibitor safely and effectively reduces proteinuria in c3 glomerulopathy","volume":"31","author":"Wong","year":"2020","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.01.041_bib22","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfab121.005","article-title":"IPTACOPAN (LNP023): a novel oral complement alternative pathway factor B inhibitor safely and effectively stabilises EGFR in C3 glomerulopathy","volume":"36","author":"Wong","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2023.01.041_bib23","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1016\/S2352-3026(21)00028-4","article-title":"Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial","volume":"8","author":"Risitano","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ekir.2023.01.041_bib24","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/bcp.14195","article-title":"Beyond \u201cintent-to-treat\u201d and \u201cper protocol\u201d: improving assessment of treatment effects in clinical trials through the specification of an estimand","volume":"86","author":"Petavy","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ekir.2023.01.041_bib26","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A\u00a0graphical approach to sequentially rejective multiple test procedures","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.ekir.2023.01.041_bib27","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.kint.2017.04.019","article-title":"Challenges in conducting clinical trials in nephrology: conclusions from a kidney disease-improving global outcomes (KDIGO) controversies conference","volume":"92","author":"Baigent","year":"2017","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.01.041_bib28","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2215\/CJN.08600718","article-title":"Proteinuria reduction as a surrogate end point in trials of IgA nephropathy","volume":"14","author":"Thompson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.01.041_bib29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.01.041_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","article-title":"Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis","volume":"78","author":"Inker","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.01.041_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1053\/j.ajkd.2021.04.003","article-title":"Using GFR, albuminuria, and their changes in clinical trials and clinical care","volume":"78","author":"Coresh","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.01.041_bib32","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.ekir.2019.08.007","article-title":"Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT Trial)","volume":"4","author":"Barratt","year":"2019","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2023.01.041_bib39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2215\/CJN.13101019","article-title":"Identifying outcomes important to patients with glomerular disease and their caregivers","volume":"15","author":"Carter","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2023.01.041_bib40","series-title":"National kidney foundation\u2019s and IgA nephropathy foundation\u2019s externally-led patient focused drug development (EL-PFDD) meeting on IgA nephropathy","year":"2019"},{"key":"10.1016\/j.ekir.2023.01.041_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s40271-021-00521-3","article-title":"Assessing patient preferences in rare diseases: direct preference elicitation in the rare chronic kidney disease, immunoglobulin A nephropathy","volume":"14","author":"Marsh","year":"2021","journal-title":"Patient"},{"key":"10.1016\/j.ekir.2023.01.041_bib43","first-page":"4715","article-title":"The contribution of complement to the pathogenesis of IgA nephropathy: are complement-targeted therapies moving from rare disorders to more common diseases?","volume":"10","author":"Poppelaars","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ekir.2023.01.041_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.732146","article-title":"Alternative complement pathway inhibition abrogates pneumococcal opsonophagocytosis in vaccine-naive, but not in vaccinated individuals","volume":"12","author":"Muri","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.01.041_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.747594","article-title":"Alternative complement pathway inhibition does not abrogate meningococcal killing by serum of vaccinated individuals","volume":"12","author":"Ispasanie","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2023.01.041_bib46","series-title":"Iptacopan, a novel oral complement factor B (FB) inhibitor, significantly reduces proteinuria and C3 deposit scores in native and transplanted kidneys C3 glomerulopathy (C3G) patients. American Society of Nephrology late-breaking ePoster #PO2536","author":"Wong","year":"2021"},{"key":"10.1016\/j.ekir.2023.01.041_bib47","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2249.2004.02627.x","article-title":"The quantitative role of alternative pathway amplification in classical pathway induced terminal complement activation","volume":"138","author":"Harboe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ekir.2023.01.041_bib48","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1053\/j.ajkd.2021.07.025","article-title":"Improving clinical trials for anticomplement therapies in complement-mediated glomerulopathies: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"79","author":"Bomback","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2023.01.041_bib49","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00281-021-00884-7","article-title":"Is IgA nephropathy the same disease in different parts of the world?","volume":"43","author":"Zhang","year":"2021","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.ekir.2023.01.041_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A\u00a0pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2023.01.041_bib51","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.kint.2021.04.002","article-title":"SGLT-2 inhibition in IgA nephropathy: the new standard of care?","volume":"100","author":"Barratt","year":"2021","journal-title":"Kidney Int"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923000505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024923000505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T12:28:00Z","timestamp":1723206480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024923000505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2468024923000505"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2023.01.041","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2023.01.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc. on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}]}}